Table 2.

Baseline characteristics for the study patients

VariablesAll patients (N = 173)Chemotherapy-naive group (n = 119)Previously treated group (n = 54)
N%n%n%
Median age, y61.56163.5
Range36–8241–8236–79
Gender
 Male1418298824380
 Female321821181120
Performance status
 03621312659
 11066169583769
 222131412815
 3211112
 Missing744335
Histologic subtype
 Epithelioid1106482692852
 Biphasic261513111324
 Sarcomatoid12710824
 Others11654611
 Unspecified1489859
Baseline white blood cell count (× 109/L)
 <8.3784553462546
 ≥8.3915362522954
Baseline platelet counts (× 109/L)
 ≤400955561513463
 >400744354452037
Hemoglobin difference (g/L)
 <10392326221324
 ≥101307589754176
Neutrophil-to-lymphocyte ratio
 <5955562523361
 ≥5734253462037
Median overall survival, mo10.611.78.0
95% CI = 9.0–12.195% CI = 7.6–15.895% CI = 3.8–12.2

Abbreviations: CI, confidence interval; EORTC, European Organisation for Research and Treatment of Cancer.